327 related articles for article (PubMed ID: 17846600)
1. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
2. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
[TBL] [Abstract][Full Text] [Related]
3. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
4. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
5. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
6. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
Radtke ML; Kolesar JM
J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
[TBL] [Abstract][Full Text] [Related]
7. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
Nasilowska-Adamska B; Szydlo R; Rzepecki P; Czyz A; Tomaszewska A; Markiewicz M; Torosian T; Bieniaszewska M; Hellman A; Jedrzejczak WW; Holowiecki J; Komarnicki M; Warzocha K; Marianska B
Ann Transplant; 2011; 16(4):47-54. PubMed ID: 22210421
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
9. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.
Nguyen DT; Shayani S; Palmer J; Dagis A; Forman SJ; Epstein J; Spielberger R
Support Care Cancer; 2015 Nov; 23(11):3141-7. PubMed ID: 25791390
[TBL] [Abstract][Full Text] [Related]
10. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
McDonnell AM; Lenz KL
Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
[TBL] [Abstract][Full Text] [Related]
11. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
[TBL] [Abstract][Full Text] [Related]
12. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
[TBL] [Abstract][Full Text] [Related]
13. Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis.
Fliedner M; Baguet B; Blankart J; Davies M; Henriques E; Leather A; Mazur E; Mihály K; Peeters L; Radványiné A; Sedlackova B
Eur J Oncol Nurs; 2007; 11 Suppl 1():S19-26. PubMed ID: 17540295
[TBL] [Abstract][Full Text] [Related]
14. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
[TBL] [Abstract][Full Text] [Related]
15. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
16. A supersaturated calcium phosphate solution seems to effectively prevent and treat oral mucositis in haematopoietic stem cell transplanted cancer patients - single centre experience.
Wasko-Grabowska A; Rzepecki P; Oborska S; Barzal J; Mlot B; Gawronski K; Wasko M; Szczylik C
J BUON; 2012; 17(2):363-8. PubMed ID: 22740219
[TBL] [Abstract][Full Text] [Related]
17. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M
J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453
[TBL] [Abstract][Full Text] [Related]
18. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT).
Stiff PJ; Erder H; Bensinger WI; Emmanouilides C; Gentile T; Isitt J; Lu ZJ; Spielberger R
Bone Marrow Transplant; 2006 Feb; 37(4):393-401. PubMed ID: 16415901
[TBL] [Abstract][Full Text] [Related]
19. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
[TBL] [Abstract][Full Text] [Related]
20. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.
Henke M; Alfonsi M; Foa P; Giralt J; Bardet E; Cerezo L; Salzwimmer M; Lizambri R; Emmerson L; Chen MG; Berger D
J Clin Oncol; 2011 Jul; 29(20):2815-20. PubMed ID: 21670447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
